Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 1101-1107

  Horvat, Mateja ^a   Prevodnik, Veronika Kloboves ^b   Lavrencak, Jaka ^b   Novakovic, Barbara Jezersek ^b  

^a doo   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

B cell lymphoma; CD20 expression; Cut off value; Disease free survival; Overall survival; Response quality; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; RITUXIMAB;

ANTIGEN EXPRESSION; ARTICLE; ASPIRATION BIOPSY; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DISEASE FREE SURVIVAL; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REFERENCE VALUE; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL SEPARATION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957326016     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000961     Document Type: Article

References (22)

1. Primic Zakelj M, Bracko M, Hocevar M, Pompe-Kirn V, Strojan P, Zadnik V, Zakotnik B and Zagar T (eds): Cancer Incidence in Slovenia 2006, Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Republic of Slovenia, 2009.
2. Cvetkovic RS and Perry CM: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs 66: 791-820, 2006.
3. Binder M, Otto F, Mertelsmann R, Veelken H and Trepel M: The epitope recognized by rituximab. Blood 108: 1975-1978, 2006.
4. Molina A: A decade of rituximab: improving survival outcomes in Non-Hodgkin's lymphoma. Annu Rev Med 59: 237-250, 2008.
5. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R and Catovsky D: Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 51: 364-369, 1998.
6. Olejniczak SH, Stewart CC, Donohue K and Czuczman MS: A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 35: 93-114, 2006.
7. Van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108: 3295-3301, 2006.
8. Cheson BD: New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am 46: 213-223, vii, 2008.
9. Schwartz A, Gaigalas AK, Wang L, Marti GE, Vogt RF and Fernandez-Repollet E: Formalization of the MESF unit of fluorescence intensity. Cytometry B Clin Cytom 57: 1-6, 2004.
10. Maury S, Huguet F, Leguay T, et al: for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL): Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica 95: 324-328, 2010.
11. Thomas DA, O'Brien S, Jorgensen JL, et al: Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 113: 6330-6337, 2009.
12. Castillo JJ, Winer ES, Stachurski D, et al: Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist 15: 293-299, 2010.
13. Canioni D, Deau-Fischer B, Taupin P, et al: Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases. PLoS One 4: E6341, 2009.
14. Johnson NA, Boyle M, Bashashati A, et al: Diffuse large B cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 113: 3773-3780, 2009.
15. Jeha S, Behm F, Pei D, et al: Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 108: 3302-3304, 2006.
16. Perz J, Topaly J, Fruehauf S, Hensel M and Ho AD: Level of CD20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 43: 149-151, 2002.
17. Weng WK and Levy R: Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98: 1352-1357, 2001.
18. Davis TA, Grillo-López AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18: 3135-3143, 2000.
19. Berinstein NL, Grillo-López AJ, White CA, et al: Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9: 995-1001, 1998.
20. Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22: 7359-7368, 2003.
21. Jazirehi AR, Vega MI and Bonavida B: Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 67: 1270-1281, 2007.
22. Czuczman MS, Olejniczak S, Gowda A, et al: Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 14: 1561-1570, 2008.